These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25941956)

  • 1. Extended-release hydrocodone (Hysingla ER) for pain.
    Med Lett Drugs Ther; 2015 May; 57(1468):71-2. PubMed ID: 25941956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrocodone Bitartrate ER (Hysingla
    Dhillon S
    Clin Drug Investig; 2016 Nov; 36(11):969-980. PubMed ID: 27718163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
    Taber L; Lynch SY; He E; Ripa SR
    Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M; Bond M; Tracewell W; Robertson P; Yang R
    Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
    Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
    Pain Med; 2016 May; 17(5):820-31. PubMed ID: 26814240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.
    Gould HJ; Paul D
    Pharmacol Res; 2015 Jan; 91():99-103. PubMed ID: 25301538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release hydrocodone (Zohydro) for pain.
    Med Lett Drugs Ther; 2014 Jun; 56(1444):45-6. PubMed ID: 24933087
    [No Abstract]   [Full Text] [Related]  

  • 9. An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing.
    Externbrink A; Sharan S; Sun D; Jiang W; Keire D; Xu X
    Int J Pharm; 2019 Apr; 561():305-313. PubMed ID: 30862508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
    Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
    Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
    Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
    Pain Med; 2017 Jul; 18(7):1278-1291. PubMed ID: 27651514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
    Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A
    Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
    Taber L; Baldridge S; He E; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):133-139. PubMed ID: 27983881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain.
    Broglio K; Pergolizzi J; Kowalski M; Lynch SY; He E; Wen W
    Pain Pract; 2017 Mar; 17(3):382-391. PubMed ID: 27317188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.
    Devarakonda K; Kostenbader K; Zheng Y; Montgomery JB; Barrett T; Young JL; Webster LR
    Postgrad Med; 2015 Jan; 127(1):13-21. PubMed ID: 25584931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
    Wen W; Taber L; Lynch SY; He E; Ripa S
    J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release hydrocodone: the devil in disguise or just misunderstood?
    Schweighardt AE; Juba KM
    Ann Pharmacother; 2014 Oct; 48(10):1362-5. PubMed ID: 25164521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.